Industry Leaders Gather in London Next Week to Discuss "Superbugs"
Superbugs & Superdrugs 2014
SMi Group releases a snap shot of attendees set to gather in London next week, to discuss superbugs and antibacterials
a unique opportunity to keep abreast of an 'old' field that is dramatically challenged
LONDON, LONDON, UNITED KINGDOM, February 24, 2014 /EINPresswire.com/ -- The 16th annual conference on Superbugs & Superdrugs, returns to London on 5th and 6th March in just over one week’s time, bringing together influential industry leaders to discuss the global threat of antibacterial resistance.— Sanofi
The conference has established itself to become a premier event in its field for over a decade and will aim to provide insights from major pharmaceutical companies, academia, senior scientists and KOLS involved in PPP funding, regulation, infectious disease, antimicrobial research and public health.
Due to limited availability, the event is looking to close registrations this week. A snap shot of attendees who have currently confirmed include:
Anacor Pharmaceuticals, Astellas Pharma Europe, Basilea Pharmaceutica , Biomedical Advanced Research and Development Authority, Brandenburg Antiinfektiva GmbH and Forschungszentrum Borstel, Cubist Pharmaceuticals, DSTL Chemical And Biological Sciences, Da Volterra, Debiopharm SA, EFPIA, Euprotec, European Commision, F. Hoffmann-La Roche, Ferrer Internacional, Genentech, Grifols America, GSK, Idenix Laboratories, Johnson and Johnson, Kings College University, KWS BioTest, MedImmune, Melinta Therapeutics, MHRA, NDA Group, Nosopharm, Office for Health Economics, PharmaConsulting, Phico Therapeutics, Polyphor, Procarta Biosystems, Roche Consumer Health, Sanofi-Aventis, SeaLife Pharma GmbH, Selcia, St George's Hospital Medical School, The Wellcome Trust, Tiber Creek Partners, TranScrip Partners, University of North Texas Health Science Center, UNTHSC, PreClinical Services, Valoralia plus many more…
Notable event highlights will include an update on the GSK and BARDA $200 million antibiotic collaboration, an address on the EU action plan presented by the Head of Infectious Disease and Public Heath from the European Commission, a panel debate on funding antibiotic research and an interactive workshop on preventing resistance in 2014 with a focus on gram negative bacteria and antibiotic stewardship.
Conference speaker Dr Michael Mourez, Therapeutic Area Leader from Sanofi commented:
"I think it is clear that there is a paradigm shift in the way Pharma companies are tackling antimicrobial research. The funding of the studies and the stance of the regulatory agencies are changing and the Pharma are responding to this by embracing these new opportunities as well as by promoting innovative approaches. This conference will bring together these different angles: market, funding and pharma to provide insights. This is a unique opportunity to keep abreast of an 'old' field that is dramatically challenged and forced to adapt fast."
For further details and to download a brochure for conference, visit www.superbugssuperdrugs.com
Superbugs and Superdrug’s: A focus on antibacterials
05-06 March 2014
Holiday Inn, Regents Park, London UK
www.superbugssuperdrugs.com
Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
